95 related articles for article (PubMed ID: 23293963)
1. Exploring structural engineering approach to formulate and characterize next-generation adjuvants.
Rattan A; Malemnganba T; Sagar ; Prajapati VK
Adv Protein Chem Struct Biol; 2024; 140():59-90. PubMed ID: 38762280
[TBL] [Abstract][Full Text] [Related]
2. Vaccine adjuvants: current status, research and development, licensing, and future opportunities.
Cui Y; Ho M; Hu Y; Shi Y
J Mater Chem B; 2024 May; 12(17):4118-4137. PubMed ID: 38591323
[TBL] [Abstract][Full Text] [Related]
3. Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.
Shakya AK; Nandakumar KS
J R Soc Interface; 2013 Feb; 10(79):20120536. PubMed ID: 23173193
[TBL] [Abstract][Full Text] [Related]
4. Small Molecule NF-κB Inhibitors as Immune Potentiators for Enhancement of Vaccine Adjuvants.
Moser BA; Escalante-Buendia Y; Steinhardt RC; Rosenberger MG; Cassaidy BJ; Naorem N; Chon AC; Nguyen MH; Tran NT; Esser-Kahn AP
Front Immunol; 2020; 11():511513. PubMed ID: 33072085
[TBL] [Abstract][Full Text] [Related]
5. Advancements in Vaccine Adjuvants: The Journey from Alum to Nano Formulations.
Moni SS; Abdelwahab SI; Jabeen A; Elmobark ME; Aqaili D; Ghoal G; Oraibi B; Farasani AM; Jerah AA; Alnajai MMA; Mohammad Alowayni AMH
Vaccines (Basel); 2023 Nov; 11(11):. PubMed ID: 38006036
[TBL] [Abstract][Full Text] [Related]
6. Call for Papers: Medicinal Chemistry of Next Generation Vaccine Adjuvants.
Salunke DB; Lindsley CW
J Med Chem; 2023 Aug; 66(15):10119-10121. PubMed ID: 37490392
[No Abstract] [Full Text] [Related]
7. Development of Drugs Based on High-Polymeric Double-Stranded RNA for Antiviral and Antitumor Therapy.
Danilenko ED; Belkina AO; Sysoeva GM
Biochem Mosc Suppl B Biomed Chem; 2019; 13(4):308-323. PubMed ID: 32288939
[No Abstract] [Full Text] [Related]
8. Ultrasound-enhanced transdermal delivery: recent advances and future challenges.
Oberli MA; Schoellhammer CM; Langer R; Blankschtein D
Ther Deliv; 2014 Jul; 5(7):843-57. PubMed ID: 25287389
[TBL] [Abstract][Full Text] [Related]
9. Skin permeabilization for transdermal drug delivery: recent advances and future prospects.
Schoellhammer CM; Blankschtein D; Langer R
Expert Opin Drug Deliv; 2014 Mar; 11(3):393-407. PubMed ID: 24392787
[TBL] [Abstract][Full Text] [Related]
10. Adjuvants: current status, clinical perspectives and future prospects.
Audibert FM; Lise LD
Immunol Today; 1993 Jun; 14(6):281-4. PubMed ID: 8104409
[TBL] [Abstract][Full Text] [Related]
11. [Adjuvants as factors improving efficiency of vaccination].
Chodaczek G
Postepy Hig Med Dosw (Online); 2004 Mar; 58():47-59. PubMed ID: 15069382
[TBL] [Abstract][Full Text] [Related]
12. Synthetic adjuvants for vaccine formulations: phytol derivatives.
Ghosh SK; Chowdhury RR
Expert Opin Drug Deliv; 2013 Apr; 10(4):437-50. PubMed ID: 23293963
[TBL] [Abstract][Full Text] [Related]
13. Synthetic adjuvants for vaccine formulations: evaluation of new phytol derivatives in induction and persistence of specific immune response.
Aachoui Y; Schulte ML; Fitch RW; Ghosh SK
Cell Immunol; 2011; 271(2):308-18. PubMed ID: 21855057
[TBL] [Abstract][Full Text] [Related]
14. Immune enhancement by novel vaccine adjuvants in autoimmune-prone NZB/W F1 mice: relative efficacy and safety.
Aachoui Y; Ghosh SK
BMC Immunol; 2011 Oct; 12():61. PubMed ID: 22024358
[TBL] [Abstract][Full Text] [Related]
15. Phytol-derived novel isoprenoid immunostimulants.
Chowdhury RR; Ghosh SK
Front Immunol; 2012; 3():49. PubMed ID: 22566931
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
